BIO-TECHNE Corp Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BIO-TECHNE Corp payments for repurchase of common stock for the quarter ending 2026-06-30 was $41.65M, a 58.37% decline year-over-year.
- BIO-TECHNE Corp payments for repurchase of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BIO-TECHNE Corp payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- BIO-TECHNE Corp payments for repurchase of common stock for the quarter ending 2025-09-30 was $24.00K.
- BIO-TECHNE Corp payments for repurchase of common stock for fiscal 2026 was $41.67M, a 84.89% decline from fiscal 2025.
- BIO-TECHNE Corp payments for repurchase of common stock for fiscal 2025 was $275.73M, a 244.48% increase from fiscal 2024.
- BIO-TECHNE Corp payments for repurchase of common stock for fiscal 2024 was $80.04M, a 309.17% increase from fiscal 2023.
- BIO-TECHNE Corp payments for repurchase of common stock for fiscal 2023 was $19.56M, a 87.85% decline from fiscal 2022.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $41.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $41.67M 10-K · filed 2026-08-24 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $100.08M derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $200.13M derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-09-30 | $24.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $100.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $275.73M 10-K · filed 2026-08-24 |
| 2025-03-31 | $100.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | |
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $80.04M 10-K · filed 2026-08-24 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-08 | |
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $19.56M 10-K · filed 2025-08-22 |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06 | $78.38M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | $139.22M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | $19.56M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $58.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $160.95M 10-K · filed 2024-08-22 |
| 2022-03-31 | $60.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $43.18M 10-K · filed 2023-08-23 |
| 2021-03-31 | $43.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-09 | |
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $50.11M 10-K · filed 2022-08-24 |
| 2020-03-31 | $50.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-07 | |
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $15.40M 10-K · filed 2021-08-25 |
| 2019-03-31 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | |
| 2018-06-30 | $0.00 10-K · filed 2020-08-26 | |
| 2015-06-30 | $0.00 10-K · filed 2015-08-31 | |
| 2014-06-30 | $0.00 10-K · filed 2015-08-31 | |
| 2013-06-30 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $1.82M 10-K · filed 2015-08-31 |
| 2013-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | $2.31M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-11 | $5.85M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-09 | $12.92M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-06-30 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $23.60M 10-K · filed 2014-08-29 |
| 2012-03-31 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | $21.28M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-12-31 | $7.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-11 | $17.75M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-09-30 | $10.68M 10-Q · filed 2012-11-09 | $10.68M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-29 | $1.94M 10-K · filed 2013-08-29 |
| 2011-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-10 | $15.52M derived: sum of 4 quarters · filed 2012-08-29 |
| 2010-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | $16.91M derived: sum of 4 quarters · filed 2012-08-29 |
| 2010-09-30 | $1.94M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-29 | $14.97M 10-K · filed 2012-08-29 |
| 2010-03-31 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-05-10 | |
| 2009-06-30 | $90.63M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |